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A B S T R A C T
Cytokine release syndrome is prevalent in severe cases of COVID-19. In this syndrome, an uncontrolled
response of immune system occurs. Extracorporeal blood purification has been proven to effectively
remove the released inflammatory cytokines. Here, we reported a successful case to represent our
experience of extracorporeal blood purification in a patient with severe COVID-19.
© 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial
Chemotherapy. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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journal home page : www.e l sev ier .com/ loca te / jgarA 54-year old man presented to the emergency department of
Erfan Niyayesh Hospital, Tehran, Iran, with complains of high-grade
fever,cough,anddyspneaforfivedays.Atadmission time,hehadfever
upto 38 C. Peripheral oxygen saturationwas 90% with a face mask.No
abnormality was seen in laboratory results except positive C-reactive
protein, lymphopenia with 570 cells/mL, and severe respiratory
acidosis. The chest X-ray imaging revealed bilateral infiltration in
both upper and lower lobs (Fig. 1a). The patient had no underlying
diseases and history of medicine usage. Reverse transcription-
polymerase chain reaction (RT-PCR) sample for COVID-19 was
reported positive and according to RT-PCR test and clinical symptoms,
the diagnosis of COVID-19 was made for the patient. The therapeutic
regimen included Hydroxychloroquine at a dose of 200 mg P.O. BID
and lopinavir/ritonavir at a dose of 200/50 mg P.O. BID initiated for the
patient. After four days, the clinical condition of the patient was
deteriorated and he was subjected to intubation for invasive
mechanical ventilation. The peripheral oxygen saturation decreased* Corresponding author.
E-mail address: iran.criticalcare@yahoo.com (S.M. Hashemian).
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ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).to 82%. The chest X-ray imaging showed the progressive infiltration
(Fig. 1b) and the patient was categorized as a critically COVID-19 case
with remarkable acute respiratory distress syndrome (ARDS). The
plasma level of interlukin-1 (IL-1), IL-6, IL-8, and tumor necrosis factor
alpha were measured at this time. The results showed high levels of
inflammatory cytokines. The urine output also decreased to 200 mL
during the last 12 h and creatinine increased to 1.5 mg/dL. At this time,
it is decided to start continuous renal replacement therapy (CRRT,
Prismaflex, Baxter, IL, USA) with disposable hemoperfusion cartridge
(HA 380 cartridge, Jafron Biomedical Co., China) due to cytokine
release storm and hypoxemia. A Shaldon catheter was inserted and
CRRT was done for three sessions. The CRRT modality was continuous
veno-venous hemofiltration (CVVH). The replacement fluid volume
was removed by 35 mL/kg/h and the pump circulated blood by
250 mL/min. Priming of hemoperfusion was done with saline, and the
cartridge was primed in a vertical positionwith the arterial side facing
downward. A bolus dose of 2500 IU of heparin was administered into
the arterial line, the cartridge was kept inlet sidedown, and blood flow
through the cartridge wasbegun. Totally, 6000 IU was neededthrough
the procedure. CRRT was started with a high ultrafiltration rate
(200 mL/h). Each cartridgewasreplacedwith a newcartridge after6 h.y for Antimicrobial Chemotherapy. This is an open access article under the CC BY-NC-
Fig. 1. The chest X-ray of the patient during hospitalization (a; admission time, b; before hemoperfusion, c; after hemoperfusion).
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zero mL/h during the last 8 h in the first 24 h. The second and the third
sessions of CRRT were conducted by 0 mL/h fluid removal. A 24-h rest
between sessions, was considered to avoid the probable coagulopathy
and electrolyte abnormality. After three sessions of CRRT plus
hemopurification, the clinical condition of the patient was improved
with the peripheral oxygen saturation of 95%. The creatinine also
decreased to 1.1 mg/dL after the end of CRRTand urine output reached
to 70 mL/h. No laboratory abnormality was seen during the CRRT. The
chest X-ray revealed recovery of both lungs following the completion
of 3 sessions of hemopurification (Fig. 1c). Also, the inflammatory
cytokines were measured 48 h following the last session of
hemoperfusion and showed a remarkable decrease. IL-1, and IL-6
were decreased from 523.3 pg/mL to 38.25 pg/mL, and 226.35 pg/mL
to 210.18 pg/mL, respectively. The measurements also showed the
decrease in IL-8 from 886.5 pg/mL to 482.4 pg/mL. Tumor necrosis
factor alpha level decreased from 49.5 pg/mL to 47.3 pg/mL at the end
of 3 sessions of hemoperfusion. The patient was finally transferred to
the ward with an acceptable clinical condition.
The “cytokine cascade” in patients with new coronavirus
(COVID-19) is a leading cause of death in critically ill patients [1]. A
variety of blood purification technology treatment methods such
as CRRT plus hemoperfusion seem to be effective in certain cases.
Cytokine release storm is the probable Phenomenon in severe
COVID-19 cases [2]. Extracorporeal organ support can not only
support vital organ functions such as the heart, lungs, kidneys, and
liver but also avoid organ damage by removing excess inflamma-
tory mediators [3]. Extracorporeal blood purification technology
has been proven to effectively eliminate inflammatory cytokines
such as CRP, IL-1, IL-6, etc. [4]. Here, we reported a successful case
to represent our experience of extracorporeal blood purification in
a patient with confirmed COVID-19. In this case, IL-6 was high and
Tocilizumab, as an IL-6 antagonist, was another potential agent.However, Tocilizumab therapy may be associated with adverse
effects and the access to Tocilizumab is limited in Iran. Also,
tocilizumab is effective only on IL-6 regarding its mechanism.
Hemoperfusion can have impact on more than one cytokine and
may be more effective. This case responded to hemoperfusion and
CRRT without remarkable complication. Hence, hemoperfusion
with a disposable cartridge may be a promising option to decrease
the inflammatory cytokines in COVID-19 induced ARDS. However,
it is necessary to conduct clinical trials to find the efficacy and
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